Novamind Inc. updated shareholders on a clinical pilot investigating the efficacy of group ketamine-assisted psychotherapy for frontline healthcare
workers ("Frontline KAP"). With the final cohort of participants expected to begin treatment in March 2022, data analysis is currently underway and will be published following completion of the clinical pilot. Frontline KAP represents a unique opportunity for Novamind to scale an innovative research
pilot into a novel treatment program and make it accessible at all Novamind clinics. The pilot launched in July 2021, in partnership with Colorado-based Wholeness Center, to address pandemic-related stress and trauma in frontline healthcare workers. Novamind's Chief Medical Officer, Dr. Reid Robison, and Wholeness Center's Dr. Scott Shannon designed a six-session KAP protocol delivered in a group setting. A cohort of 40 participants are enrolled in the pilot across research sites in Utah and Colorado. Ketamine has demonstrated efficacy for rapid relief from symptoms of depression, while the group setting provides a platform for processing trauma with peers, more effectively building community and reducing feelings of isolation compared to individual treatment. Frontline KAP involves a ratio of two therapists to four patients per cohort, greatly reducing the total number of therapist hours when compared to traditional one-on-one treatment, which increases the treatment's affordability and enables Novamind to serve a larger patient population.